Eurofins-Cerep S.A. (ALECR.PA)
Eurofins-Cerep S.A. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Vienne, FR. The stock last traded at $16100.00, up 0.00% on the session, giving a market capitalisation of $81.2M. Its beta of 0.01 implies it has historically moved less than the broad market.
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
Eurofins-Cerep S.A. is most often compared with the following Healthcare names: